title: The anti-obesity effect of rimonabant is associated with an improved serum lipid profile.
abstract: We investigated the effects of chronic treatment with the CB1 receptor antagonist rimonabant (10 mg/kg/day p.o. for 10 weeks) in mice with established obesity (5-month high-fat diet). Untreated obese mice showed a weight gain of 46% (45.0 +/- 0.6 g vs. 30.8 +/- 0.5 g) compared with age-matched animals fed a standard diet. Rimonabant treatment, commencing after 5-month high-fat diet, produced a marked and sustained decrease in body weight (34.5 +/- 0.8 g vs. 47.2 +/- 0.5 g in the high-fat vehicle group, p < 0.001). The anti-obesity effect of rimonabant was similar to that obtained by switching obese mice from high-fat diet to standard laboratory diet during 10 weeks (final weight 33.7 +/- 0.6 g) and was associated with only transient (14 days) reduction in energy intake. Serum leptin, insulin and glucose levels were markedly elevated in obese animals. Rimonabant treatment significantly reduced these elevations (leptin -81%, insulin -78%, glucose -67%, p < 0.001 in all cases vs. high-fat vehicle group). In addition, rimonabant treatment modestly but significantly increased serum adiponectin levels (+18%, p < 0.05 vs. high-fat vehicle group). Obese mice demonstrated abnormal serum lipid profiles. Although rimonabant did not modify high-density lipoprotein cholesterol (HDLc) and had modest effects on total cholesterol, it significantly reduced triglycerides and low-density lipoprotein cholesterol (LDLc) and, notably, increased the HDLc/LDLc ratio (12.4 +/- 0.8 vs. 7.9 +/- 0.2 in high-fat vehicle group, p < 0.001). Therefore, in a model of established obesity, chronic rimonabant treatment produces a marked and sustained decrease in body weight (equivalent to that achieved by dietary change) which is associated with favourable modifications in serum biochemical and lipid profiles.
authors.affiliation: Cardiovascular-Thrombosis Department, Sanofi-Synthélabo Research, 91835 Chilly-Mazarin Cedex, France. bruno.poirier@sanofi-synthelaboc.om
authors.forename: B
authors.initials: B
authors.lastname: Poirier
authors.forename: J-P
authors.initials: JP
authors.lastname: Bidouard
authors.forename: C
authors.initials: C
authors.lastname: Cadrouvele
authors.forename: X
authors.initials: X
authors.lastname: Marniquet
authors.forename: B
authors.initials: B
authors.lastname: Staels
authors.forename: S E
authors.initials: SE
authors.lastname: O'Connor
authors.forename: P
authors.initials: P
authors.lastname: Janiak
authors.forename: J-M
authors.initials: JM
authors.lastname: Herbert
mesh_terms: D052242:Adiponectin; D000818:Animals; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D007328:Insulin / Q000097:blood; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood; D020738:Leptin / Q000097:blood; D008055:Lipids / Q000097:blood*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009765:Obesity / Q000097:blood / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D000077285:Rimonabant
chemical_list: D052242:Adiponectin; D019440:Anti-Obesity Agents; D001786:Blood Glucose; D008076:Cholesterol, HDL; D007328:Insulin; D036341:Intercellular Signaling Peptides and Proteins; D020738:Leptin; D008055:Lipids; D010880:Piperidines; D011720:Pyrazoles; D002784:Cholesterol; D000077285:Rimonabant